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ABSTRACT
Objective: The study evaluates the long-term deferasirox treatment of adult and pediatric
patients with chronic transfusional iron overload in clinical practice.
Methods: In this non-interventional study, patients were observed for up to 3 years from
initiation of deferasirox treatment both prospectively and retrospectively for up to 1 year
prior to enrollment. The primary end points were the proportion of patients with ≥1 notable
increase in serum creatinine (SCr), and ≥1 notable increase in alanine aminotransferase (ALT).
Results: Overall, 120 patients were enrolled and 51 completed the study, with a limited 3-year
dropout rate of 12.5% due to adverse events (AEs). Increase in SCr > 33% above baseline and the
age-adjusted ULN (upper limit of normal) was observed in 14 patients (95%CI, 7.1–19.2). The ALT
levels >5 × ULN was observed in 1 patient. Most frequent AEs reported during treatment with
deferasirox include gastrointestinal disturbances.
Conclusions: The long-term treatment with deferasirox was manageable in most transfusion-
dependent patients with no unexpected safety ﬁndings. Regular monitoring and an adjusted
deferasirox dosing strategy per local labels allowed continued iron chelation treatment and
control of transfusional iron in the majority of patients on study.
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1. Introduction
Patients with thalassemia, sickle-cell disease (SCD),
myelodysplastic syndromes (MDS), and other transfu-
sion-dependent anemias require long-term red blood
cell transfusions. Long-term iron chelation therapy is
required in regularly transfused patients to manage
chronic iron overload and associated risks [1–3]. Cur-
rently, three main iron chelators are available for
clinical use: deferoxamine, deferiprone, and defera-
sirox. The once-daily oral deferasirox dispersible
tablet formulation, available since 2005, oﬀered an
improved option with greater compliance over par-
enteral deferoxamine [3–6]. The eﬃcacy and safety
of deferasirox dispersible tablet have been well
deﬁned through an extensive clinical trial program
in adult and pediatric patients with a variety of
transfusion-dependent anemias in adult and pedi-
atric patients aged ≥2 years [7–11]. The present
study reports the results of a post-marketing active
surveillance program for deferasirox. The aim of
the study was to evaluate the long-term safety
and clinical management of deferasirox in adult
and pediatric patients aged ≥2 years with chronic
transfusional iron overload in the actual practice
setting.
2. Materials and methods
2.1. Study design
This was a global, non-interventional study (July 2011–
October 2015) conducted on 14 sites in four countries
(Egypt, Jordan, Spain and UK). The data were collected
for 3 years from the initiation of treatment with defer-
asirox (Exjade®). The registry did not impose a therapy
protocol, diagnostic/therapeutic interventions, or a
strict visit schedule. Patients were treated with defera-
sirox in clinical practice settings, at the discretion of the
investigator, and as per local country prescribing infor-
mation. Retrospective data were collected in patients
who had treatment with deferasirox for up to 1 year
prior to enrollment.
2.2. Key inclusion/exclusion criteria
Male or female patients aged ≥2 years and treated with
deferasirox for transfusional hemosiderosis in accord-
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ance with the local prescription information, patients
who were either starting treatment with deferasirox
at the time of enrollment or currently under treatment
with deferasirox up to 12 months prior to enrollment
were observed in this study. In order to assess the
primary end point, only patients with available baseline
values for serum creatinine (SCr) and alanine amino-
transferase (ALT) measured up to a maximum period
of 45 days prior to the ﬁrst dose of deferasirox were
included. Exclusion criteria included the following:
patients with non-transfusional hemosiderosis and
patients treated with deferasirox in an interventional
clinical trial. Patients (or parents/guardians) provided
written informed consent prior to any screening pro-
cedures. The study was conducted according to the
ethical principles of the Declaration of Helsinki.
2.3. Assessments
The primary objective was to evaluate the long-term
safety of deferasirox treatment in adult and pediatric
patients aged ≥2 years with chronic transfusional iron
overload in actual practice setting. The two co-
primary end points were the proportion of patients
(within a maximum of 3 years of observation) with
the following: (1) at least one increase in SCr, deﬁned
as >33% above baseline and the age-adjusted upper
limit of normal (ULN) on at least two consecutive
measurements (≥7 days apart); and (2) at least one
increase in ALT, deﬁned as >5 × ULN on at least two
consecutive measurements (≥7 days apart). A
secondary objective was to evaluate the long-term
eﬃcacy of deferasirox as measured by serum ferritin
(SF) levels over a period of 3 years. Secondary objec-
tives also included the evaluation of safety as measured
by adverse events (AEs), laboratory parameters, renal
histology, cardiac magnetic resonance (CMR), electro-
cardiograms (ECGs), echocardiography, vital signs,
audiometry, and ophthalmology assessments.
2.4. Statistical evaluations
The full analysis set (FAS) consisted of all patients who
received at least one dose of deferasirox during the
study. The FAS was used for the statistical analysis of
SF levels. The safety set consisted of all patients who
received at least one dose of deferasirox during the
study and had at least one post-baseline safety assess-
ment. The primary end point was performed based on
the safety set. Data are presented in mean ± SD or
median (range).
3. Results
3.1. Patient demographics and clinical
characteristics
The majority of the patients included in the study were
diagnosed with β thalassemia (n = 49), SCD (n = 31),
MDS (n = 21), and other transfusion-dependent
anemias (n = 19). The mean (±SD) age was 28.9 ± 29.0
in the study population, 7.5 ± 4.2 years in patients
<18 years (n = 69) and 57.9 ± 22.1 years in patients
Table 1. Demographics and baseline data by age group.
Characteristics
<18 years
(n = 69)
≥18 years
(n = 51)
All patients
(n = 120)
Mean age, years 7.5 57.9 28.9
SD 4.2 22.1 29.0
Female: Male, n 35:34 21:30 56:64
Race, n (%)
Caucasian 37 (53.6) 44 (86.3) 81 (67.5)
Black 21 (30.4) 6 (11.8) 27 (22.5)
Asian 7 (10.1) 0 (0.0) 7 (5.8)
Native American 0 (0.0) 1 (2.0) 1 (0.8)
Other 4 (5.8) 0 (0.0) 4 (3.3)
Disease, n (%)
β thalassemia major 34 (49.3) 7 (13.7) 41 (34.2)
β thalassemia intermedia 7 (10.1) 1 (2.0) 8 (6.7)
Refractory anemia 0 (0.0) 2 (3.9) 2 (1.7)
Sideroblastic anemia 0 (0.0) 3 (5.9) 3 (2.5)
Myelodysplastic syndrome 0 (0.0) 21 (41.2) 21 (17.5)
Diamond–Blackfan anemia 2 (2.9) 0 (0.0) 2 (1.7)
Hemolytic anemia 0 (0.0) 1 (2.0) 1 (0.8)
Sickle cell disease (SS or Sbeta zero or both) 24 (34.8) 7 (13.7) 31 (25.8)
Other 2 (2.9) 9 (17.6) 11 (9.2)
History of blood transfusions
Mean ± SD, time since start of blood transfusions* (years) 4.3 ± 4.0 8.7 ± 12.9 6.1 ± 9.1
Total number of blood transfusions received (median) 33.0 29.0 30.0
Patients with prior chelation therapy, n(%)
Deferoxamine 17 (24.6) 12 (23.5) 29 (24.2)
Deferiprone 23 (33.3) 3 (5.9) 26 (21.7)
Deferoxamine + deferiprone 0 1 (2.0) 1 (0.8)
Deferasirox 1 (1.4) 13 (25.5) 14 (11.7)
Duration of exposure to deferasirox
Median 36.0 10.0 29.9
Mean 30.6 15.1 23.9
*Time since start of blood transfusions = (ﬁrst study drug dose date – start of blood transfusion date + 1)/365.25.
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≥18 years (n = 51). The median number of blood trans-
fusions before entering into the study was 30.0 (<18
years, 33.0; ≥18 years, 29.0), with the majority of
patients requiring bi-weekly (16.7%) or monthly
(62.5%) blood transfusions (Table 1).
3.2. Patient disposition
The ﬁrst patient ﬁrst visit was July 2011, and the last
patient last visit was October 2015. A total of 120
patients with transfusional hemosiderosis were
enrolled (<18 years, n = 69 and ≥18 years, n = 51).
The FAS included all 120 patients, and the safety analy-
sis set included 117 patients. Sixty-nine patients
(57.5%) discontinued the study. Fifteen (12.5%) of
these discontinuations were related to AEs and more
commonly observed in adult patients (25.5%) com-
pared to pediatric patients (2.9%). The reasons for
study discontinuation are presented in Table 2.
3.3. Exposure to deferasirox treatment
The median average of actual dose of deferasirox was
23.3 mg/kg/day (range, 2.3–41.3). The median duration
of deferasirox exposure was 29.9 months (range, 0.8–
39.2). The median dose of deferasirox with relation to
blood intake in patients ≥18 years was 12.5 and
23.7 mg/kg/day with low (<7 mL/kg/day) and inter-
mediate (7–14 mL/kg/day) transfusional burden,
respectively. Based on serum ferritin level, deferasirox
was adjusted or interrupted according to the local
label.
3.4. Dose reductions or interruptions
In the overall population, 55 patients (47.0%) had dose
reductions or interruptions. The mean number of dose
reductions or interruptions was 1.7 in all patients. The
most common reasons for patients with at least one
dose reduction or interruption were AEs (27.4%) and
others (20.5%) (including, but were not limited to,
dose adjustment for weight, improvement/decrease
in SF, drug unavailability, investigator decision, and
patients discontinued taking drug therapy due to an
error).
3.5. Prior iron chelation therapy
Overall, 54.2% of patients (n = 65) were chelation-naïve
and 45.8% (n = 55) received prior iron chelation
therapy. Evaluable chelation-naïve patients received a
lower average actual dose (mg/kg/day, mean ± SD) of
deferasirox compared to patients receiving prior iron
chelation therapy (<18 years, 23.8 ± 5.2 vs. 27.6 ± 7.4;
≥18 years, 15.4 ± 7.7 vs. 20.3 ± 9.7).
3.6. Safety parameters
3.6.1. Adverse events
Overall, 40 patients (34.2%) had AEs suspected to be
related to study drug. The most common AEs (>3%
in the overall patient population) are presented in
Figure 1. Deferasirox-related AEs gradually decreased
over time (Figure 2(A)) for patients continuing on
study.
Serious adverse events, suspected to be related to
study drug, were reported in ﬁve patients (4.3%); the
most frequently reported being gastrointestinal
hemorrhage (n = 2). A total of 99 patients (84.6%) had
at least 1 AE regardless of relationship to the study
drug. Overall incidence of AEs regardless of relation-
ship with deferasirox also decreased over time
(Figure 2(B)) for patients continuing on study. The
most common AEs were gastrointestinal disorders,
(43.6%; n = 51) and infections and infestations (43.6%;
n = 51). Adverse events occurring in >10% of patients
were vomiting (16.2%), pyrexia (15.4%), diarrhea
(13.7%), cough (12.8%), abdominal pain (12.0%), head
Table 2. Overall patient disposition by age group.
Disposition reason
<18 years
(n = 69)
n (%)
≥18 years
(n = 51)
n (%)
All patients
(n = 120)
n (%)
Patients treated
Completed study 45 (65.2) 6 (11.8) 51 (42.5)
Discontinued study, n (%) 24 (34.8) 45 (88.2) 69 (57.5)
Subject’s condition no longer requires study drug 7 (10.1) 16 (31.4) 23 (19.2)
Adverse event(s) 2 (2.9) 13 (25.5) 15 (12.5)a
Consent withdrawal 9 (13.0) 4 (7.8) 13 (10.8)
Lost to follow-up 6 (8.7) 2 (3.9) 8 (6.7)
Deathb 0 7 (13.7) 7 (5.8)
Protocol deviation 0 2 (3.9) 2 (1.7)c
Disease progression 0 1 (2.0) 1 (0.8)
aDisposition for an additional seven patients who discontinued due to both an adverse event and
death is accounted for under the most severe outcome (death).
bOnly on-treatment deaths from day 1 to the day of last study drug +30 days are provided; 1
additional death occurred during the study; this patient discontinued due to a protocol deviation
and died within 30 days of stopping treatment.
cOne patient who discontinued due to a protocol deviation died within 30 days after stopping
treatment (on-treatment death).
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Figure 1. Adverse events (>3% in the overall patient population) suspected to be related to the study drug. Note: SCr, serum
creatinine.
Figure 2. Number of patients with adverse events over time (n = 117). (A) Patients with adverse events suspected to be related to
deferasirox over time (by underlying disease). (B) Patients with adverse events regardless of relationship to deferasirox over time (by
underlying disease).
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ache (10.3%), and upper respiratory tract infection
(10.3%). Most patients had normal auditory and
ocular results during the study. For audiometric test
results, a 7-year-old male patient had three clinically
signiﬁcant abnormalities (moderately severe sensori-
neural aﬀection at high frequencies, bilaterally lost
acoustic reﬂexes, and mild bilateral sensorineural
hearing loss at high frequencies) and an AE of neuro-
sensory deafness, which was suspected to be related
to study drug, was reported for the same patient. The
patient withdrew consent and did not complete the
study. Two patients had clinically signiﬁcant abnormal-
ities for ocular examinations. One 7-year-old female
patient had the most extreme post-baseline results of
two possible inferior visual ﬁeld defects, and the
second 48-year-old female patient had a baseline
result of sickle-cell retinopathy and vitreous hemor-
rhage in the right eye. The two patients did not com-
plete the study, as their condition no longer required
the study drug.
Eight on-treatment deaths (6.8%) were reported, all
in patients ≥18 years, mainly due to neoplasms (acute
leukemia, n = 1; acute lymphocytic leukemia, n = 1) and
gastrointestinal complications (gastrointestinal hemor-
rhage, n = 1; intestinal ischemia, n = 1). None of these
deaths were suspected to be related to the study drug.
3.6.1.1. Adverse events leading to discontinuation of
study drug. Adverse events leading to discontinuation
of the study drug occurred in 22 patients (18.8%). Of
these patients, 11 (9.4% [17.6% vs. 3.0% for ≥18 years
vs. <18 years]) had AEs suspected to be related to the
study drug. The most common AEs (>2%) leading to
discontinuation regardless of relationship with study
drug were increased SCr (3.4%) and diarrhea (2.6%),
both of which occurred only in patients aged ≥18
years.
3.6.2. Laboratory parameters
3.6.2.1. Serum creatinine. Increase in SCr > 33% above
baseline and the age-adjusted ULN in at least two
Table 3. Patients with increase in serum creatinine or alanine aminotransferase.
Criteria
<18
years
n = 66
≥18
years
n = 51
All
patients
n = 117 95% CI
Patients with at least 1 episode of SCr increase from baseline >33% and >age-adjusted ULN at 2
consecutive visits (≥7 days apart)
8 (12.1) 6 (11.8) 14 (12.0) 7.1,
19.2
Patients with at least 1 episode of ALT > 5 × ULN at 2 consecutive visits (≥7 days apart) 1 (1.5) 0 1 (0.9) 0.0, 5.2
Notes: ALT, alanine aminotransferase; CI, conﬁdence interval; SCr, serum creatinine; ULN, upper limit of normal.
Figure 3. Distribution of (A) serum creatinine and (B) alanine aminotransferase over time. Notes: Boxes indicate median ± 25th/75th
centile. The means are presented as dots, and medians of time points are connected over time. ALT, alanine aminotransferase.
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consecutive measurements (≥7 days apart) was
observed in 14 patients (12%; 95% conﬁdence interval
[CI], 7.1–19.2) with MDS (n = 3), SCD (n = 7), and other
anemias (n = 4) (Table 3). Of these a higher proportion
of patients aged <18 years (78.8%) had SCr values
≤ULN during treatment as compared to patients with
≥18 years (37.3%). In the overall study population,
the total SCr by quarters showed non-progressive,
stable SCr values over the 3 years (Figure 3(A)). Due
to increased SCr, ﬁve patients had dose adjustments
or interruptions, and four patients discontinued,
which were suspected to be related to drug. During
the study, in the overall population, 55 patients had a
conﬁrmed creatinine clearance (CrCl) ≥ 90 mL/min,
and 9 patients had conﬁrmed CrCl of 60 – <90 mL/
min on 2 consecutive measurements (≥7 days apart).
3.6.2.2. Alanine aminotransferase
Of the eight patients, <18 years of age who presented
with single events of elevated ALT >5 × ULN and >2 ×
baseline during the study period, four had an under-
lying diagnosis of β thalassemia and four had SCD.
None of the patients discontinued study drug due to
elevated liver function tests (LFTs); reasons for the
increased LFTs were not apparent. Six of the eight
patients (75%) completed the study, despite transient
events of increased ALT, and two of the eight patients
ended the study because the investigator judged
deferasirox as no longer necessary. All pediatric
patients except one were chelation naïve while starting
deferasirox.
Of the two patients (1.7%) aged ≥18 years who
exhibited single events of elevated ALT (>5 × ULN
and >2 × baseline), one had an underlying diagnosis
of MDS and ended the study due to increased SCr.
The other patient received a stem cell transplant with
curative intent for the underlying chronic lymphocytic
leukemia and this patient ended the study because
deferasirox was deemed by the investigator as no
longer needed.
Increase in ALT >5 × ULN in at least two consecutive
measurements (≥7 days apart) was observed in one
patient (0.9%; 95% CI, 0.0–5.2) with β thalassemia
(baseline ALT missing) (Table 3). In the overall popu-
lation, the total ALT showed no apparent trend, with
some ﬂuctuations over time during the 3 years
(Figure 3(B)). Increased ALT lead to dose adjustments
or interruptions in two patients (1.7%; β thalassemia
[n = 2]) aged <18 years. None of the patients discontin-
ued because of increased ALT.
3.7. Long-term eﬃcacy of deferasirox
In the overall patient population, mean SF levels
decreased from 2373 μg/L (range, 298–8317) to
2110 μg/L (range, 151–9954) from baseline to end of
study. In the overall population, >50% of the patients
had decreased SF compared to baseline with a mean
change of −223 μg/L. In patients aged <18 years,
mean SF levels decreased from 2445 (range, 298–
8317) to 2170 (range, 151–9954), whereas in patients
>18 years of age, mean SF levels decreased from
2246 (range, 490–7500) to 2004 (range, 317–8250). A
higher proportion of the overall patient population
had SF values ≤1000 µg/L at the end of the observation
period (27.5%) than at the start of deferasirox treat-
ment (13.3%) (Figure 4).
4. Discussion
The observational study reported the long-term safety
of deferasirox in adult and pediatric patients aged ≥2
years with chronic transfusional iron overload at enroll-
ment. In this study, 52.7% of patients discontinued
treatment. The overall duration of deferasirox treat-
ment in the present 3-year study was 29.9 months.
The total time on study drug was 26.9 months when
accounting for reported dose interruptions. Thus,
patients received a daily dose of deferasirox in 90%
of days on chelation treatment indicating an accepta-
ble overall safety proﬁle.
In this study, there was a low discontinuation rate
due to AEs, particularly in patients aged <18 years indi-
cating deferasirox was manageable in pediatric
patients as well as in overall patient population.
Although no direct comparison can be made across
clinical trials, it seems that the rate of completion of
patients treated with deferasirox in this observational
trial is in line with the results obtained in the 4-year
extension of a phase 2 study involving pediatric and
adult patients with transfusional hemosiderosis.
The highest percentage of pediatric patients in the
present study was in the β thalassemia major and the
second highest in SCD, which is expected for the
most common red blood cell disorders diagnosed in
infancy. In this study, the majority of the patients
were Caucasians (67.5%), followed by Blacks (22.5%),
Asians (5.8%), and others (3.3%). This distribution is in
line with the general association of diagnosis of thalas-
semia and MDS being more prevalent among Cauca-
sians and SCD being more prevalent in Black patients.
The most frequent AEs reported during the treat-
ment with deferasirox in adult and pediatric patients
were related to GI disturbances in about 26% of
patients (mainly nausea, vomiting, diarrhea, or abdomi-
nal pain). Notable increases in SCr and liver function
tests were observed in some patients, and those
increases were consistent with the known safety
proﬁle of deferasirox. In deferasirox registration
studies [9–11], which included patients with transfu-
sional siderosis, elevations in SCr of >33% on ≥2 con-
secutive visits, sometimes > ULN, occurred in about
36% of patients. In the present study, the proportion
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of patients with SCr > ULN at two consecutive visits at
least 7 days apart was 12% during the 3-year obser-
vation period. Furthermore, the total SCr in all patients
showed only a slight increase in SCr levels, remaining
stable over time during the 3-year observation
period. An evaluation of the change of renal function
in the adult population in the present study is limited
by the relatively high number of missing values (n =
40, 78.4%). It is of note that renal safety in the study
population may be attributable to various factors and
not limited to iron chelation treatment. Renal abnorm-
alities in patients with transfusion-dependent siderosis
were previously reported in the literature and suggest
that iron overload and anemia are likely to contribute
to renal dysfunction [12,13]. A recent study evaluating
long-term renal safety in Italian patients who partici-
pated in deferasirox registration studies, indicated no
progressive or late change in renal function for patients
exposed to deferasirox and other chelation treatment
for up to 13 years [14].
The renal safety was also supported by a slight initial
decrease in CrCl, which remained stable in most
patients throughout the study and is consistent with
the data from previous studies that have shown an
early initial drop in CrCl, followed by stabilization [15].
Deferasirox has also been shown to be associated
with a mild reversible hemodynamic eﬀect on renal
function in patients receiving short-term and long-
term treatments [16]. Renal parameters remained
stable indicating no further decline in renal function
over time. The ﬁndings observed from the current
study were consistent with the 5-year renal data from
the pivotal registration study, indicated no progressive
worsening of the renal function over time on the basis
of SCr and CrCl monitoring [17].
In a 5-year analysis within the deferasirox
program, elevations of transaminases >10 × ULN
were uncommon (0.3%). Furthermore, there was an
initial increase in ALT levels during the ﬁrst 2 years
of deferasirox treatment following a downward
trend for the remainder of the study [17]. The
increase in ALT could potentially be attributed to
iron overload, which is known to increase liver
enzyme levels, particularly in patients with high
liver iron concentration due to continued transfusion
dependence [18]. There was no apparent relationship
between deferasirox dose and liver transaminase
increases [17]. In this observational study, ALT levels
>5 × ULN in at least two consecutive post-baseline
measurements at least 7 days apart was observed
in one patient and no patients in the study popu-
lation discontinued due to increases in ALT.
Figure 4. Median absolute change in serum ferritin (µg/L) values from baseline over time by the underlying disease. Notes: †Absol-
ute change refers to change of serum ferritin values at each time point from baseline. *End of study refers to the last available post-
baseline serum ferritin value.
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A lower deferasirox median dose in relation to blood
intake was observed mainly in adult patients with low
transfusional burden compared to adult patients with
intermediate burden. This observation suggests that
dose adjustments are either multifactorial taking into
account other clinical parameters or that patient may
not be adequately dose adjusted as the transfusional
iron burden increases over time.
Most of the patients had normal auditory and ocular
results during the study, with few patients having clini-
cally signiﬁcant auditory or ocular abnormalities. Of the
120 observed patients in this study, one pediatric
patient discontinued the study with neurosensory
aﬀection of hearing. Most other observed impairments
of hearing in the pediatric population were conductive,
transitory, and assessed not to be related to the study
treatment.
A 4-year extension study of the phase 2 study in an
SCD patient population demonstrated a median absol-
ute change in SF from the start of treatment with defer-
asirox to the end of study and its 95% CI of −246 μg/L
(−530; 402) in patients receiving deferasirox through-
out the study [15]. The analysis of SF levels in the 5-
year observational study, in a mixed population of
pediatric patients with iron overload including SCD,
also demonstrated a better reduction in SF of
−576 μg/L [19]. During this study, a proportion of
patients with SCD (>50%) had an initial increase in SF
at 6 months before they start to have a negative
balance. Overall, the SF was moderately reduced from
baseline to the end of the study for the majority of
patients.
Approximately, 43% of patients completed the
global 3-year post-authorization safety study, with a
3-year dropout rate of 12.5% due to AEs in all patients
and 2.9% in patients aged <18 years. None of the ﬁve
deaths occurring during the study were observed in
pediatric patients or suspected to be related to study
treatment. Thus, the data further add evidence that
chronic iron chelation therapy with deferasirox is man-
ageable in a pediatric patient population, as well as in
the overall patient population. Notable increases in SCr
and liver function tests were observed in some
patients, and those increases were consistent with
the known safety proﬁle of deferasirox.
Limitations of this study were high discontinuation
rate (57.5%) and usage of SF levels to adjust the defer-
asirox dosage instead of using T2-MRI, which is more
accurate.
In conclusion, the data from this 3-year, non-inter-
ventional study of deferasirox in adult and pediatric
patients with chronic transfusional iron overload were
consistent with the known safety proﬁle of deferasirox
with no unexpected or accumulative events during
observation. Regular monitoring and an adjusted
deferasirox dosing strategy per local labels allow
eﬀective management of most AEs for long-term
chelation and control of transfusional iron in the
majority of patients in clinical practice.
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